Advertisement covers CROI 2014

What Major HIV Research Developments Does 2014 Hold in Store?

April 4, 2014


Antonio Urbina, M.D.

Easier Adherence and PrEP

"I was very excited about the new GSK compound, the new integrase inhibitor. It has a very long half-life, but what's more interesting is that there's these new formulations where persons with HIV or at risk for HIV could potentially give themselves intramuscular injections that could last up to three months. So I think that could be a really big breakthrough, in terms of really solving this whole issue around adherence to antiretrovirals."

-- Antonio Urbina, M.D., Associate Medical Director, Spencer Cox Center for Health, St. Luke's-Roosevelt Hospital, New York.

This article was provided by It is a part of the publication The 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014).


Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.